Our products / APIs
Colistimethate sodium
Colistimethate sodium is a prodrug of colistin (polymyxin E) which is a mixture of polypeptide antibiotics active against gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.
Indication: Used in the treatment of acute or chronic infections due to sensitive strains of gram-negative pathogens, especially in patients with limited treatment options.
Application: Administered systemically as intramuscular injections and intravenous injections or infusions. Colistimethate sodium can also be administered intrathecally, by intraventricular administration, by inhalation or mixed with bone cement.
Downloadables
Product grades
Sterile, micronized
Sterile, non-micronized
Non-sterile, non-micronized
Packaging sizes
Sterile, micronized
10 BOU (Billion Of Units)
Sterile, non-micronized
15 BOU (Billion Of Units)
65 BOU (Billion Of Units)
Non-sterile, non-micronized
15 BOU (Billion Of Unit)
65 BOU (Billion Of Unit)
Packaging material
Primary: Aluminum containers with polyethylene insert and polypropylene lid
Secondary: Polystyrene
Shelf life
5 years
Storage conditions
Do not store above 25 °C (77 °F)
Compliance
Ph. Eur., USP
Manufacturing site
Xellia Pharmaceuticals ApS, Copenhagen, Denmark
Release site
Xellia Pharmaceuticals ApS, Copenhagen, Denmark
Site registered
EU GMP issued by Danish Medicines Agency
US FDA
Other health authorities
Regulatory documentation
EU Drug Master File (DMF)/Certificate of Suitability (CEP)
US Drug Master File (DMF)
China Drug Master File (CDMF for sterile grade)
Japan Drug Master File (JDMF)
DMF also available in other selected countries outside EU/US/China/Japan
Want to hear more about our products?